What blood pressure medication is recommended for patients with heart failure, considering factors such as diabetes, chronic kidney disease, and intolerance to certain medications like Angiotensin-Converting Enzyme (ACE) inhibitors?

Blood Pressure Medications for Heart Failure

ACE inhibitors are the first-line blood pressure medication for patients with heart failure, with specific agents like enalapril, lisinopril, ramipril, captopril, and trandolapril proven to reduce mortality, hospitalizations, and improve quality of life. 1

Primary Recommendation: ACE Inhibitors

ACE inhibitors should be initiated in all patients with heart failure unless contraindicated, as they provide the most robust mortality benefit among blood pressure medications. 1 The evidence demonstrates that ACE inhibitors prevent 13 deaths per 1000 patient-years of treatment and reduce hospital admissions by 99 per 1000 patient-years. 1

Specific ACE Inhibitor Dosing

Start with low doses and titrate upward every 2 weeks to target doses: 1

• Enalapril: Start 2.5 mg twice daily → Target 10-20 mg twice daily
• Lisinopril: Start 2.5-5.0 mg once daily → Target 30-35 mg once daily
• Ramipril: Start 2.5 mg once daily → Target 5 mg twice daily or 10 mg once daily
• Captopril: Start 6.25 mg three times daily → Target 50-100 mg three times daily
• Trandolapril: Start 1.0 mg once daily → Target 4 mg once daily

Higher doses provide greater benefit—the ATLAS study showed that high-dose lisinopril (32.5-35 mg daily) reduced death or hospitalization by 12% compared to low doses (2.5-5 mg daily). 2

Monitoring During ACE Inhibitor Therapy

Monitor blood chemistry (urea, creatinine, potassium) and blood pressure at baseline, 1-2 weeks after initiation, and 1-2 weeks after each dose increase. 1

Alternative: Angiotensin Receptor Blockers (ARBs)

If ACE inhibitors are not tolerated due to cough or other side effects, substitute an ARB such as losartan. 1 ARBs provide similar benefits to ACE inhibitors in heart failure patients. 1 The 2020 ESC guidelines recommend ACE inhibitors or ARBs in patients with heart failure with reduced LVEF (<40%), diabetes, or chronic kidney disease to reduce all-cause and cardiovascular mortality. 1

When to Use ARBs

ARBs are specifically indicated when: 1

• ACE inhibitor-induced cough is severe enough to stop the patient from sleeping
• The cough recurs after ACE inhibitor withdrawal and rechallenge, proving it is drug-related
• Other ACE inhibitor side effects are intolerable

Essential Companion Therapy: Beta-Blockers

Beta-blockers must be added to ACE inhibitors as first-line therapy for heart failure. 1 Only three beta-blockers have proven mortality reduction: bisoprolol, carvedilol, and metoprolol succinate extended-release. 3

Beta-blockers prevent 38 deaths per 1000 patient-years and reduce hospitalizations by 65 per 1000 patient-years. 1 The mortality benefit (34-38% relative risk reduction) is equal to or greater than ACE inhibitors. 3

Evidence-Based Beta-Blocker Dosing

3

• Bisoprolol: Start 1.25 mg once daily → Target 10 mg once daily
• Carvedilol: Start 3.125 mg twice daily → Target 25-50 mg twice daily
• Metoprolol succinate ER: Start 12.5-25 mg once daily → Target 200 mg once daily

Start beta-blockers only after the patient is stable and euvolemic on ACE inhibitor therapy. 4 Double the dose every 2 weeks as tolerated. 3

Additional Therapy: Mineralocorticoid Receptor Antagonists

Spironolactone should be added in patients with NYHA class III-IV heart failure, as it prevents 57 deaths per 1000 patient-years and reduces hospitalizations by 138 per 1000 patient-years—the highest benefit among all agents. 1 The ESC guidelines give MRAs a Class I recommendation for patients with heart failure with reduced LVEF (<40%). 1

Critical Cautions and Contraindications

When to Seek Specialist Advice Before Starting ACE Inhibitors

1

• Significant renal dysfunction (creatinine >2.5 mg/dL or >221 µmol/L)
• Hyperkalemia (>5.0 mmol/L)
• Symptomatic or severe hypotension (systolic BP <90 mmHg)

Managing Common Problems

Asymptomatic low blood pressure: No change in therapy needed. 1

Symptomatic hypotension: 1

1. Reconsider nitrates, calcium channel blockers, and other vasodilators—reduce or stop these first
2. If no signs of congestion, consider reducing diuretic dose
3. Only if above measures fail, seek specialist advice

Cough: ACE inhibitor-induced cough rarely requires discontinuation. 1 Exclude pulmonary edema first. If cough is proven drug-related and severely disruptive, substitute an ARB. 1

Worsening renal function: Some rise in creatinine is expected and acceptable—this represents the trade-off for long-term renal protection. 5 A slight reduction in GFR at onset correlates with better long-term outcomes. 5

Special Populations

Patients with Chronic Kidney Disease

ACE inhibitors are safe and beneficial in chronic renal failure, though clinical efficacy may be limited. 6 The fall in filtration pressure contributes to antiproteinuric effects and long-term renoprotection. 5 Monitor renal function closely and adjust doses carefully. 5

Patients with Diabetes

ACE inhibitors are particularly important in diabetic patients with heart failure, as they reduce cardiovascular mortality and morbidity. 1 However, diabetic patients have increased risk for renal function impairment with ACE inhibitors. 6

Patients on Diuretics

Withdraw diuretics 1-2 days before starting ACE inhibitors to restore intravascular volume and minimize risk of hypotension and acute renal failure. 6 Start with low doses of ACE inhibitors. 6

Common Pitfalls to Avoid

• Underdosing: Aim for target doses proven in clinical trials—some ACE inhibitor is better than none, but higher doses provide greater benefit. 1, 2
• Stopping ACE inhibitors for asymptomatic hypotension: Low blood pressure without symptoms requires no intervention. 1
• Using metoprolol tartrate instead of metoprolol succinate: Only the extended-release succinate formulation reduces mortality in heart failure. 3
• Initiating beta-blockers in unstable patients: Beta-blockers should only be started in stable, euvolemic patients. 4
• Premature discontinuation for cough: Most ACE inhibitor cough does not require stopping the medication. 1